Gisela Lilja1, Niklas Nielsen2, Hans Friberg2, Janneke Horn2, Jesper Kjaergaard2, Fredrik Nilsson2, Tommaso Pellis2, Jørn Wetterslev2, Matt P Wise2, Frank Bosch2, John Bro-Jeppesen2, Iole Brunetti2, Azul Forti Buratti2, Christian Hassager2, Caisa Hofgren2, Angelo Insorsi2, Michael Kuiper2, Alice Martini2, Nicki Palmer2, Malin Rundgren2, Christian Rylander2, Annelou van der Veen2, Michael Wanscher2, Helen Watkins2, Tobias Cronberg2. 1. From Department of Neurology and Rehabilitation Medicine (G.L., T.C.), Department of Intensive and Perioperative Care (H.F., M.R.), and Research and Development Centre, Unit for Medical Statistics and Epidemiology (F.N.), Skåne University Hospital, Lund, Sweden; Department of Clinical Sciences, Lund University, Lund, Sweden (G.L., N.N., H.F., M.R., T.C.); Department of Anesthesiology and Intensive Care, Helsingborg Hospital, Helsingborg, Sweden (N.N.); Department of Intensive Care, Academic Medical Center, Amsterdam, The Netherlands (J.H., M.K., A.v.d.V.); Department of Cardiology, The Heart Centre (J.K., J.B.-J., C. Hassager), Copenhagen Trial Unit, Centre for Clinical Intervention Research (J.W.), and Department of Cardiothoracic Anesthesiology, The Heart Centre (M.W.), Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; Department of Anaesthesia, Intensive Care, and Emergency Medical Service, Santa Maria degli Angeli Hospital, Pordenone, Italy (T.P., A.M.); Adult Critical Care, University Hospital of Wales, Cardiff, UK (M.P.W., N.P., H.W.); Department of Intensive Care, Rijnstate Hospital, Arnhem, The Netherlands (F.B.); Department of Anaesthesia and Intensive Care, IRCCS San Martino IST, University of Genoa, Italy (I.B., A.I.); Academic Unit of Child and Adolescent Psychiatry, Imperial College, London, UK (A.F.B.); Institute of Neuroscience and Physiology, Section of Clinical Neuroscience and Rehabilitation Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden (C. Hofgren); Department of Intensive Care, Medical Center Leeuwarden, The Netherlands (M.K.); and Department of Anesthesiology and Intensive Care, Sahlgrenska University Hospital, Gothenburg, Sweden (C.R.). gisela.lilja@med.lu.se. 2. From Department of Neurology and Rehabilitation Medicine (G.L., T.C.), Department of Intensive and Perioperative Care (H.F., M.R.), and Research and Development Centre, Unit for Medical Statistics and Epidemiology (F.N.), Skåne University Hospital, Lund, Sweden; Department of Clinical Sciences, Lund University, Lund, Sweden (G.L., N.N., H.F., M.R., T.C.); Department of Anesthesiology and Intensive Care, Helsingborg Hospital, Helsingborg, Sweden (N.N.); Department of Intensive Care, Academic Medical Center, Amsterdam, The Netherlands (J.H., M.K., A.v.d.V.); Department of Cardiology, The Heart Centre (J.K., J.B.-J., C. Hassager), Copenhagen Trial Unit, Centre for Clinical Intervention Research (J.W.), and Department of Cardiothoracic Anesthesiology, The Heart Centre (M.W.), Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; Department of Anaesthesia, Intensive Care, and Emergency Medical Service, Santa Maria degli Angeli Hospital, Pordenone, Italy (T.P., A.M.); Adult Critical Care, University Hospital of Wales, Cardiff, UK (M.P.W., N.P., H.W.); Department of Intensive Care, Rijnstate Hospital, Arnhem, The Netherlands (F.B.); Department of Anaesthesia and Intensive Care, IRCCS San Martino IST, University of Genoa, Italy (I.B., A.I.); Academic Unit of Child and Adolescent Psychiatry, Imperial College, London, UK (A.F.B.); Institute of Neuroscience and Physiology, Section of Clinical Neuroscience and Rehabilitation Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden (C. Hofgren); Department of Intensive Care, Medical Center Leeuwarden, The Netherlands (M.K.); and Department of Anesthesiology and Intensive Care, Sahlgrenska University Hospital, Gothenburg, Sweden (C.R.).
Abstract
BACKGROUND: Target temperature management is recommended as a neuroprotective strategy after out-of-hospital cardiac arrest. Potential effects of different target temperatures on cognitive impairment commonly described in survivors have not been investigated sufficiently. The primary aim of this study was to evaluate whether a target temperature of 33°C compared with 36°C was favorable for cognitive function; the secondary aim was to describe cognitive impairment in cardiac arrest survivors in general. METHODS AND RESULTS: Study sites included 652 cardiac arrest survivors originally randomized and stratified for site to temperature control at 33°C or 36°C within the Target Temperature Management trial. Survival until 180 days after the arrest was 52% (33°C, n=178/328; 36°C, n=164/324). Survivors were invited to a face-to-face follow-up, and 287 cardiac arrest survivors (33°C, n=148/36°C, n=139) were assessed with tests for memory (Rivermead Behavioural Memory Test), executive functions (Frontal Assessment Battery), and attention/mental speed (Symbol Digit Modalities Test). A control group of 119 matched patients hospitalized for acute ST-segment-elevation myocardial infarction without cardiac arrest performed the same assessments. Half of the cardiac arrest survivors had cognitive impairment, which was mostly mild. Cognitive outcome did not differ (P>0.30) between the 2 temperature groups (33°C/36°C). Compared with control subjects with ST-segment-elevation myocardial infarction, attention/mental speed was more affected among cardiac arrest patients, but results for memory and executive functioning were similar. CONCLUSIONS:Cognitive function was comparable in survivors of out-of-hospital cardiac arrest when a temperature of 33°C and 36°C was targeted. Cognitive impairment detected in cardiac arrest survivors was also common in matched control subjects with ST-segment-elevation myocardial infarction not having had a cardiac arrest. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01946932.
RCT Entities:
BACKGROUND: Target temperature management is recommended as a neuroprotective strategy after out-of-hospital cardiac arrest. Potential effects of different target temperatures on cognitive impairment commonly described in survivors have not been investigated sufficiently. The primary aim of this study was to evaluate whether a target temperature of 33°C compared with 36°C was favorable for cognitive function; the secondary aim was to describe cognitive impairment in cardiac arrest survivors in general. METHODS AND RESULTS: Study sites included 652 cardiac arrest survivors originally randomized and stratified for site to temperature control at 33°C or 36°C within the Target Temperature Management trial. Survival until 180 days after the arrest was 52% (33°C, n=178/328; 36°C, n=164/324). Survivors were invited to a face-to-face follow-up, and 287 cardiac arrest survivors (33°C, n=148/36°C, n=139) were assessed with tests for memory (Rivermead Behavioural Memory Test), executive functions (Frontal Assessment Battery), and attention/mental speed (Symbol Digit Modalities Test). A control group of 119 matched patients hospitalized for acute ST-segment-elevation myocardial infarction without cardiac arrest performed the same assessments. Half of the cardiac arrest survivors had cognitive impairment, which was mostly mild. Cognitive outcome did not differ (P>0.30) between the 2 temperature groups (33°C/36°C). Compared with control subjects with ST-segment-elevation myocardial infarction, attention/mental speed was more affected among cardiac arrestpatients, but results for memory and executive functioning were similar. CONCLUSIONS: Cognitive function was comparable in survivors of out-of-hospital cardiac arrest when a temperature of 33°C and 36°C was targeted. Cognitive impairment detected in cardiac arrest survivors was also common in matched control subjects with ST-segment-elevation myocardial infarction not having had a cardiac arrest. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01946932.
Authors: Joel Kohler; Friedrich Borchers; Matthias Endres; Björn Weiss; Claudia Spies; Julius Valentin Emmrich Journal: Dtsch Arztebl Int Date: 2019-09-20 Impact factor: 5.594
Authors: Jerry P Nolan; Robert A Berg; Stephen Bernard; Bentley J Bobrow; Clifton W Callaway; Tobias Cronberg; Rudolph W Koster; Peter J Kudenchuk; Graham Nichol; Gavin D Perkins; Tom D Rea; Claudio Sandroni; Jasmeet Soar; Kjetil Sunde; Alain Cariou Journal: Intensive Care Med Date: 2017-03-11 Impact factor: 17.440
Authors: Jerry P Nolan; Robert A Berg; Clifton W Callaway; Laurie J Morrison; Vinay Nadkarni; Gavin D Perkins; Claudio Sandroni; Markus B Skrifvars; Jasmeet Soar; Kjetil Sunde; Alain Cariou Journal: Intensive Care Med Date: 2018-06-02 Impact factor: 17.440
Authors: Melika Hosseini; Robert H Wilson; Christian Crouzet; Arya Amirhekmat; Kevin S Wei; Yama Akbari Journal: Neurotherapeutics Date: 2020-04 Impact factor: 7.620
Authors: Sachin Agarwal; Alex Presciutti; William Roth; Elizabeth Matthews; Ashley Rodriguez; David J Roh; Soojin Park; Jan Claassen; Ronald M Lazar Journal: Crit Care Med Date: 2018-02 Impact factor: 7.598
Authors: Patrick J Coppler; Kelly N Sawyer; Chun Song Youn; Seung Pill Choi; Kyu Nam Park; Young-Min Kim; Joshua C Reynolds; David F Gaieski; Byung Kook Lee; Joo Suk Oh; Won Young Kim; Hyung Jun Moon; Benjamin S Abella; Jonathan Elmer; Clifton W Callaway; Jon C Rittenberger Journal: Ther Hypothermia Temp Manag Date: 2016-07-15 Impact factor: 1.286
Authors: Aleksander Trąbka-Zawicki; Marek Tomala; Aleksander Zeliaś; Elżbieta Paszek; Wojciech Zajdel; Ewa Stępień; Krzysztof Żmudka Journal: Cardiol J Date: 2017-07-11 Impact factor: 2.737